Aker BioMarine’s Science Board Meets to Talk Krill

October 18, 2011

Among items discussed, the Aker BioMarine Science Board (ABS) talked about existing data supporting krill oil and omega-3 phospholipids, as well as ongoing clinical trials with Aker BioMarine’s Superba krill oil and global increases in omega-3 consumption and supplementation.

At its first meeting at the beginning of October, Aker BioMarine’s (Oslo, Norway) new science board met to discuss the future of krill phospholipid omega-3s.

Among items discussed, the Aker BioMarine Science Board (ABS) talked about existing data supporting krill oil and omega-3 phospholipids, as well as ongoing clinical trials with Aker BioMarine’s Superba krill oil and global increases in omega-3 consumption and supplementation.

Aker says that its board will provide the company with strategic guidance on ongoing research and product development, including in vitro, preclinical, and clinical studies.